Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Diagonal Bio

0,00 SEK

0,00 %

Mindre end 1K følgere

DIABIO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
0,00 %
-20,00 %
-50,00 %
-63,64 %
-62,93 %
-73,01 %
-98,83 %
-
-99,89 %

Diagonal Bio operates in biotechnology. The company develops a platform for detecting and diagnosing small sections of pathogen genomes, such as viruses, bacteria and fungi. In addition to its main business, it also offers service and related ancillary services. Diagonal Bio's operations are operated with the largest presence in Sweden. The company was founded in 2020 and is headquartered in Lund.

Læs mere
Markedsværdi
6,56 mio. SEK
Aktieomsætning
12,14 t SEK
Omsætning
60 t
EBIT %
-15.700 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning t

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
27.2
2026

Årsrapport '25

18.5
2026

Delårsrapport Q1'26

19.5
2026

Generalforsamling '26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse1.12.2025, 07.30

Nomination Committee appointed for Diagonal Bio

Diagonal Bio
Pressemeddelelse4.11.2025, 08.30

Untersteiner Racing signs agreement for a pilot test

Diagonal Bio
Selskabsmeddelelse31.10.2025, 07.00

Diagonal Bio publishes interim report for the third quarter of 2025

Diagonal Bio

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse13.10.2025, 07.00

Diagonal Bio launches new website to reflect commercial focus on the Animal Health segment

Diagonal Bio
Pressemeddelelse3.10.2025, 09.30

Diagonal Bio initiates collaboration with SVA on evaluation of coronavirus in horses

Diagonal Bio
Selskabsmeddelelse23.9.2025, 09.15

Diagonal Bio expands horse testing panel to detect Equine Herpesvirus type 2

Diagonal Bio
Selskabsmeddelelse18.9.2025, 11.00

Diagonal Bio receives order from Stall Courant

Diagonal Bio
Selskabsmeddelelse22.8.2025, 06.00

Diagonal Bio publishes interim report for the second quarter of 2025

Diagonal Bio
Pressemeddelelse20.8.2025, 06.00

Diagonal Bio AB receives patent approval in Japan

Diagonal Bio
Pressemeddelelse7.7.2025, 11.00

Diagonal Bio AB files patent application for Novel Computational Method that significantly improves LAMP primer design

Diagonal Bio
Selskabsmeddelelse25.6.2025, 11.00

The Board of Directors of Diagonal Bio carries out a directed issue to underwriters in connection with exercise of warrants of series TO 2

Diagonal Bio
Selskabsmeddelelse19.6.2025, 11.40

Diagonal Bio receives SEK 3.6 million through exercise of warrants of series TO 2

Diagonal Bio
Selskabsmeddelelse17.6.2025, 16.47

Update regarding large shareholder’s exercise of warrants of series TO 2

Diagonal Bio
Selskabsmeddelelse17.6.2025, 06.30

Diagonal Bio expands equine panel with addition of strangles

Diagonal Bio
Selskabsmeddelelse16.6.2025, 06.30

Large shareholder exercises warrants of series TO 2

Diagonal Bio
Selskabsmeddelelse13.6.2025, 06.00

Last day of trading in Diagonal Bio’s warrants of series TO 2 is 16 June 2025

Diagonal Bio
Pressemeddelelse11.6.2025, 09.30

Diagonal Bio shares progress update on LAMPlify® commercial pilots

Diagonal Bio
Selskabsmeddelelse9.6.2025, 12.00

Svea Bank AB invests SEK 0.5 million in Diagonal Bio AB through the exercise of warrants of series TO 2

Diagonal Bio
Selskabsmeddelelse4.6.2025, 06.30

The exercise period for Diagonal Bio’s warrants of series TO 2 starts today

Diagonal Bio
Selskabsmeddelelse20.5.2025, 12.00

Bulletin from the Annual General Meeting on 20 May 2025 in Diagonal Bio AB

Diagonal Bio
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.